EA201491965A1 - Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина - Google Patents
Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулинаInfo
- Publication number
- EA201491965A1 EA201491965A1 EA201491965A EA201491965A EA201491965A1 EA 201491965 A1 EA201491965 A1 EA 201491965A1 EA 201491965 A EA201491965 A EA 201491965A EA 201491965 A EA201491965 A EA 201491965A EA 201491965 A1 EA201491965 A1 EA 201491965A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- selection
- relates
- ospovaccine
- proteins
- slip
- Prior art date
Links
- 108700005091 Immunoglobulin Genes Proteins 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 5
- 102000018358 immunoglobulin Human genes 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 229940072221 immunoglobulins Drugs 0.000 abstract 3
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Изобретение относится к высокоэффективному способу экспрессии молекул иммуноглобулинов в эукариотических клетках. Изобретение, кроме того, относится к способу получения библиотек тяжелых и легких цепей иммуноглобулинов, в частности, с использованием способа тримолекулярной рекомбинации для экспрессии в эукариотических клетках. Изобретение, кроме того, относится к способам отбора и скрининга антигенспецифических молекул иммуноглобулинов, и их антигенспецифических фрагментов. Изобретение относится также к наборам для получения, скрининга и отбора антигенспецифических молекул иммуноглобулинов. Наконец, изобретение относится к молекулам иммуноглобулинов и их антигенспецифических фрагментам, полученным способами, представленными в настоящем документе.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639046P | 2012-04-26 | 2012-04-26 | |
US201261732776P | 2012-12-03 | 2012-12-03 | |
US13/844,388 US9708601B2 (en) | 2012-04-26 | 2013-03-15 | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
PCT/US2013/038497 WO2013163602A1 (en) | 2012-04-26 | 2013-04-26 | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491965A1 true EA201491965A1 (ru) | 2015-03-31 |
EA028164B1 EA028164B1 (ru) | 2017-10-31 |
Family
ID=49477810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491965A EA028164B1 (ru) | 2012-04-26 | 2013-04-26 | Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина |
Country Status (16)
Country | Link |
---|---|
US (3) | US9708601B2 (ru) |
EP (1) | EP2841606B1 (ru) |
JP (2) | JP6498599B2 (ru) |
KR (1) | KR102108589B1 (ru) |
CN (1) | CN104520444B (ru) |
AU (1) | AU2013251371B2 (ru) |
CA (1) | CA2871597C (ru) |
DK (1) | DK2841606T3 (ru) |
EA (1) | EA028164B1 (ru) |
ES (1) | ES2725673T3 (ru) |
IL (1) | IL235323B (ru) |
NZ (1) | NZ630854A (ru) |
PL (1) | PL2841606T3 (ru) |
PT (1) | PT2841606T (ru) |
SG (1) | SG11201406974YA (ru) |
WO (1) | WO2013163602A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗cd100抗体およびこれを使用するための方法 |
SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
EP3107567A4 (en) * | 2014-02-19 | 2017-10-25 | Cangene Corporation | Methods of modulating an immune response |
KR20170019080A (ko) | 2015-08-11 | 2017-02-21 | 주식회사 엘티전자 | 플렉시블 사이니지 장치 |
EP3402520A4 (en) | 2016-01-14 | 2019-01-02 | BPS Bioscience, Inc. | Anti-pd-1 antibodies and uses thereof |
MX2018012818A (es) * | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus. |
IL264343B2 (en) | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells |
EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | 4D ANTI-SEMAPHORIN HUMAN ANTIBODY |
MX2022013930A (es) * | 2020-05-06 | 2022-11-30 | Vaccinex Inc | Despliegue de la proteina de membrana integral en viriones con envoltura extracelular de poxvirus. |
US20240093177A1 (en) | 2022-06-10 | 2024-03-21 | Vaccinex, Inc. | Methods to select antibodies specific to complex membrane antigens |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5445953A (en) | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
AU694519B2 (en) | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
DE69839970D1 (de) | 1998-11-10 | 2008-10-16 | Univ Rochester | Methoden zu herstellung von genbanken |
EP1268763A2 (en) | 2000-03-28 | 2003-01-02 | University Of Rochester | Methods of producing a library and methods of selecting polynucleotides |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
AU2001297872B2 (en) * | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
AU2002255495A1 (en) | 2001-02-02 | 2002-08-19 | University Of Rochester | Methods of identifying regulator molecules |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
WO2005055936A2 (en) | 2003-12-04 | 2005-06-23 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
KR101377116B1 (ko) | 2004-08-27 | 2014-03-24 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 면역 및 자가면역의 조절제로서의 세라마이드 유도체 |
US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
US7858599B2 (en) | 2005-12-30 | 2010-12-28 | Hander Robert W | Enhancement of urogenital function |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
KR101642846B1 (ko) | 2007-12-26 | 2016-07-26 | 백시넥스 인코포레이티드 | 항-c35 항체 병용 치료 및 방법 |
CA2725383C (en) * | 2008-05-28 | 2018-09-25 | Ruxandra Draghia-Akli | Smallpox dna vaccine and the antigens therein that elicit an immune response |
US20100081575A1 (en) | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
NZ593794A (en) | 2009-01-08 | 2013-04-26 | Einstein Coll Med | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗cd100抗体およびこれを使用するための方法 |
WO2011110642A2 (en) * | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
JP6008842B2 (ja) * | 2010-05-04 | 2016-10-19 | ファイブ プライム セラピューティックス インコーポレイテッド | Csf1rに結合する抗体 |
RU2012153241A (ru) * | 2010-05-11 | 2014-06-20 | Авео Фармасьютикалз, Инк. | Антитела к fgfr2 |
AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
WO2012006341A2 (en) * | 2010-07-06 | 2012-01-12 | Aveo Pharmaceuticals, Inc. | Anti-ron antibodies |
EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
CA2804029A1 (en) | 2010-07-07 | 2012-01-12 | Steven A. Porcelli | Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
JP5925768B2 (ja) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | 骨形成促進剤 |
SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
AU2013225812B2 (en) | 2012-03-02 | 2017-11-30 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス, インコーポレイテッド | 免疫グロブリンaのレベルを増大するための方法 |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
MX2018012818A (es) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus. |
IL264343B2 (en) | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells |
SG11201906670PA (en) | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
JP7159187B2 (ja) | 2017-03-20 | 2022-10-24 | バクシネックス インコーポレーティッド | セマフォリン-4d抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法 |
EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | 4D ANTI-SEMAPHORIN HUMAN ANTIBODY |
-
2013
- 2013-03-15 US US13/844,388 patent/US9708601B2/en active Active
- 2013-04-26 EP EP13780660.0A patent/EP2841606B1/en active Active
- 2013-04-26 CA CA2871597A patent/CA2871597C/en active Active
- 2013-04-26 CN CN201380033060.7A patent/CN104520444B/zh active Active
- 2013-04-26 EA EA201491965A patent/EA028164B1/ru not_active IP Right Cessation
- 2013-04-26 PL PL13780660T patent/PL2841606T3/pl unknown
- 2013-04-26 AU AU2013251371A patent/AU2013251371B2/en active Active
- 2013-04-26 DK DK13780660.0T patent/DK2841606T3/da active
- 2013-04-26 SG SG11201406974YA patent/SG11201406974YA/en unknown
- 2013-04-26 NZ NZ630854A patent/NZ630854A/en unknown
- 2013-04-26 JP JP2015509201A patent/JP6498599B2/ja active Active
- 2013-04-26 WO PCT/US2013/038497 patent/WO2013163602A1/en active Application Filing
- 2013-04-26 KR KR1020147033046A patent/KR102108589B1/ko active IP Right Grant
- 2013-04-26 ES ES13780660T patent/ES2725673T3/es active Active
- 2013-04-26 PT PT13780660T patent/PT2841606T/pt unknown
-
2014
- 2014-10-23 IL IL235323A patent/IL235323B/en active IP Right Grant
-
2015
- 2015-12-21 US US14/977,067 patent/US9701958B2/en active Active
-
2017
- 2017-06-12 US US15/619,790 patent/US10662422B2/en active Active
-
2018
- 2018-11-01 JP JP2018206485A patent/JP2019055956A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2725673T3 (es) | 2019-09-26 |
CA2871597C (en) | 2021-04-20 |
NZ630854A (en) | 2017-03-31 |
US9708601B2 (en) | 2017-07-18 |
WO2013163602A1 (en) | 2013-10-31 |
KR102108589B1 (ko) | 2020-05-07 |
EA028164B1 (ru) | 2017-10-31 |
AU2013251371A1 (en) | 2014-11-13 |
JP6498599B2 (ja) | 2019-04-10 |
DK2841606T3 (da) | 2019-05-06 |
JP2015514811A (ja) | 2015-05-21 |
EP2841606B1 (en) | 2019-01-23 |
US20160152971A1 (en) | 2016-06-02 |
CA2871597A1 (en) | 2013-10-31 |
IL235323B (en) | 2020-01-30 |
EP2841606A1 (en) | 2015-03-04 |
KR20150009560A (ko) | 2015-01-26 |
US20170306318A1 (en) | 2017-10-26 |
SG11201406974YA (en) | 2014-11-27 |
US20130288927A1 (en) | 2013-10-31 |
CN104520444A (zh) | 2015-04-15 |
CN104520444B (zh) | 2017-12-12 |
EP2841606A4 (en) | 2015-12-30 |
US10662422B2 (en) | 2020-05-26 |
PT2841606T (pt) | 2019-05-17 |
AU2013251371B2 (en) | 2018-01-04 |
PL2841606T3 (pl) | 2019-07-31 |
JP2019055956A (ja) | 2019-04-11 |
US9701958B2 (en) | 2017-07-11 |
IL235323A0 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491965A1 (ru) | Слитые белки для облегчения отбора клеток, инфицированных рекомбинантным вирусом осповакцины с геном специфического иммуноглобулина | |
CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
CY1119925T1 (el) | Aνti-cd40 αντισωματα, χρησεις και μεθοδοι | |
CY1119717T1 (el) | Παραγωγη δεσμευτικων μοριων | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
CY1118928T1 (el) | Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους | |
NZ627977A (en) | Humanized rodents that express heavy chains containing vl domains | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
EP3786183A3 (en) | Antigen binding constructs to cd3 | |
TR201901668T4 (tr) | Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler. | |
MX353278B (es) | Raton con cadena ligera comun. | |
WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
DK2681244T3 (da) | Cea-antistoffer | |
MX2015012540A (es) | Ratón de cadena ligera común. | |
MX2013013832A (es) | Proteínas de unión receptoras fc. | |
CA2872308A1 (en) | Novel ha binding agents | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
EA201300819A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |